{
    "clinical_study": {
        "@rank": "67323", 
        "arm_group": {
            "arm_group_label": "Haploidentical stem cell transplant", 
            "arm_group_type": "Experimental", 
            "description": "This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI)."
        }, 
        "brief_summary": {
            "textblock": "This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant\n      (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen, consisting of\n      fludarabine, cyclophosphamide and low dose total body irradiation (TBI), is designed for the\n      treatment of patients with advanced and/or high risk diseases."
        }, 
        "brief_title": "Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases", 
        "completion_date": {
            "#text": "June 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Leukemias", 
            "Burkitt's Lymphoma", 
            "Chronic Myelogenous Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Burkitt Lymphoma", 
                "Hematologic Diseases", 
                "Leukemia", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Lymphoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must be <75 years old with no 7/8 or 8/8 HLA-matched sibling donor\n\n          -  One or more potential related mismatched donors (e.g. biologic parent (s) or siblings\n             (full or half) or children). Low resolution using DNA based typing at HLA-A, -B and\n             -DRB1 for potential haploidentical donors is required.\n\n          -  All diseases listed below are advanced hematologic malignancies not curable by\n             conventional chemotherapy. Responses to conventional treatment range from zero to 30%\n             but are typically short lived.\n\n               -  Acute Lymphoblastic Leukemia (ALL) in first complete remission (CR1) that is NOT\n                  considered favorable-risk.\n\n               -  Acute Myelogenous Leukemia (AML) in first complete remission (CR1) that is NOT\n                  considered as favorable-risk.\n\n               -  Acute Leukemias in 2nd or subsequent CR\n\n               -  Biphenotypic/Undifferentiated/Prolymphocytic Leukemias in first or subsequent\n                  CR, adult T-cell leukemia/lymphoma in first or subsequent CR\n\n               -  Burkitt's lymphoma in CR2 or subsequent CR\n\n               -  Natural killer cell malignancies after response to initial therapy\n\n               -  Chronic myelogenous leukemia: all types except refractory blast crisis.\n\n               -  Large-cell lymphoma, Hodgkin lymphoma and multiple myeloma with chemotherapy\n                  sensitive disease that has failed or patients who are ineligible for an\n                  autologous transplant.\n\n               -  Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone\n                  B-cell lymphoma, follicular lymphoma, which have progressed within 12 months of\n                  achieving a partial or complete remission.\n\n               -  Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are\n                  eligible after initial therapy if chemotherapy sensitive.\n\n               -  Refractory leukemia or MDS These patients may be taken to transplant in aplasia\n                  after induction or re-induction chemotherapy or radiolabeled antibody.\n\n               -  Bone marrow failure syndromes, except for Fanconi Anemia\n\n               -  Myeloproliferative syndromes\n\n          -  Adequate organ function is defined as:\n\n               -  Cardiac: Absence of decompensated congestive heart failure, or uncontrolled\n                  arrhythmia and left ventricular ejection fraction > 35%. For children that are\n                  not able to cooperate with MUGA and echocardiography, such should be clearly\n                  stated in the physician's note\n\n               -  Pulmonary: DLCO > 30% predicted, and absence of O2 requirements. For children\n                  that are not able to cooperate with PFTs, a pulse oximetry with exercise should\n                  be attempted. If nether test can be obtained it should be clearly stated in the\n                  physician's note.\n\n               -  Liver: Transaminases < 5 x upper limit of normal and bilirubin < 3 x upper limit\n                  of normal\n\n               -  Renal: serum creatinine < 2.0 mg/dl (adults) or glomerular filtration rate (GFR)\n                  >40 mL/min/1.73m2 (peds). Patients with a creatinine > 1.2 mg/dl or a history of\n                  renal dysfunction must have glomerular filtration rate (GFR) > 40 mL/min/1.73m2.\n\n               -  Adequate performance status is defined as Karnofsky score \u2265 60% (> 16 years of\n                  age) or Lansky score \u2265 50 (pediatrics)\n\n          -  If recent mold infection e.g. Aspergillus - must have minimum of 30 days of\n             appropriate treatment before BMT and infection controlled and be cleared by\n             Infectious Disease.\n\n          -  Second BMT: Must be > 3 months after prior myeloablative transplant.\n\n          -  Patients must be ineligible for autologous transplantation due to prior autologous\n             transplant, an inadequate autologous stem cell harvest, inability to withstand a\n             myeloablative preparative regimen, or clinically aggressive/high risk disease.\n\n          -  Patients are eligible for transplantation if there is no evidence of progressive\n             disease by imaging modalities or biopsy. Persistent PET activity, though possibly\n             related to lymphoma, is not an exclusion criterion in the absence of CT changes\n             indicating progression.\n\n          -  Patients with stable disease are eligible for transplantation if the largest residual\n             nodal mass is < 5 cm (approximately). For patients who have responded to preceding\n             therapy, the largest residual mass must represent a 50% reduction and be < 7.5 cm\n             (approximately).\n\n          -  Voluntary written consent (adult or parental/guardian)\n\n        Exclusion Criteria:\n\n          -  Available and clinically suitable 5-6/6 HLA-A, B, DRB1 matched sibling donor\n\n          -  Pregnant or breastfeeding\n\n          -  Evidence of HIV infection or known HIV positive serology\n\n          -  Current active serious infection\n\n          -  Unless in post-chemotherapy and radioimmunoconjugated antibody induced aplasia, when\n             he/she would be eligible, patients with acute leukemia in morphologic relapse/\n             persistent disease defined as > 5% blasts in normocellular bone marrow OR any %\n             blasts if blasts have unique morphologic markers (e.g. Auer rods) or associated\n             cytogenetic markers that allows morphologic relapse to be distinguished are not\n             eligible.\n\n          -  CML in refractory blast crisis\n\n          -  Large cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressive on\n             salvage therapy. Stable disease is acceptable to move forward provided it is\n             non-bulky.\n\n          -  active central nervous system malignancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02145039", 
            "org_study_id": "2013OC116", 
            "secondary_id": "MT2013-33C"
        }, 
        "intervention": [
            {
                "arm_group_label": "Haploidentical stem cell transplant", 
                "description": "Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.", 
                "intervention_name": "Fludarabine", 
                "intervention_type": "Drug", 
                "other_name": "Fludara"
            }, 
            {
                "arm_group_label": "Haploidentical stem cell transplant", 
                "description": "Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Haploidentical stem cell transplant", 
                "description": "TBI 200cGy on day -1 before transplant.", 
                "intervention_name": "Total Body Irradiation", 
                "intervention_type": "Radiation", 
                "other_name": "TBI"
            }, 
            {
                "arm_group_label": "Haploidentical stem cell transplant", 
                "description": "Non-T-cell depleted bone marrow infusion", 
                "intervention_name": "Haploidentical stem cell transplant", 
                "intervention_type": "Biological", 
                "other_name": "HSCT"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Fludarabine monophosphate", 
                "Fludarabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Acute Lymphoblastic Leukemia (ALL)", 
            "Acute Myelogenous Leukemia (AML)", 
            "Burkitt's lymphoma", 
            "Natural killer cell malignancies", 
            "Chronic myelogenous leukemia", 
            "Myelodysplastic syndrome", 
            "Large-cell lymphoma", 
            "Hodgkin lymphoma", 
            "Multiple myeloma", 
            "Chronic lymphocytic leukemia (CLL)", 
            "Small lymphocytic lymphoma (SLL)", 
            "Marginal zone B-cell lymphoma", 
            "Follicular lymphoma", 
            "Lymphoplasmacytic lymphoma", 
            "Mantle-cell lymphoma", 
            "Prolymphocytic leukemia", 
            "Refractory leukemia", 
            "MDS", 
            "Bone marrow failure syndromes", 
            "Myeloproliferative syndromes"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "contact": {
                "email": "nbejanya@umn.edu", 
                "last_name": "Nelli Bejanyan, MD", 
                "phone": "612-624-6982"
            }, 
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55455"
                }, 
                "name": "University of Minnesota Masonic Cancer Center"
            }, 
            "investigator": {
                "last_name": "Nelli Bejanyan, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Reduced Intensity Conditioning (RIC) and Transplantation of HLA-Haploidentical Related Bone Marrow (Haplo-BM) For Patients With Hematologic Diseases", 
        "overall_contact": {
            "email": "nbejanya@umn.edu", 
            "last_name": "Nelli Bejanyan, MD", 
            "phone": "612-624-6982"
        }, 
        "overall_official": {
            "affiliation": "University of Minnesota - Clinical and Translational Science Institute", 
            "last_name": "Nelli Bejanyan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of patients that survive 2 years post-transplant", 
            "measure": "2 year survival", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02145039"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of hematopoietic engraftment", 
                "safety_issue": "No", 
                "time_frame": "42 days"
            }, 
            {
                "description": "Incidence of chimerism at day 100, 6 months and 1 year", 
                "measure": "Incidence of chimerism", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Incidence of acute GVHD at 100 days", 
                "safety_issue": "No", 
                "time_frame": "100 days"
            }, 
            {
                "measure": "Incidence of chronic GVHD at 1 year", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Incidence of transplant related mortality (TRM)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Masonic Cancer Center, University of Minnesota", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Masonic Cancer Center, University of Minnesota", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}